Bioprocessing 101

What are biologics?

An ordinary drug is a small, simple molecule; a biologic is a large one, roughly a thousand times bigger.

Think of aspirin: 21 atoms, a formula you can draw, and a set of chemical steps to build it. Most older medicines are like this – small, simple, and made by pure chemistry.

A monoclonal antibody (mAb) is different. It is a large molecule of about 25,000 atoms – roughly a thousand times the size of aspirin – and it is not a tidy formula but long chains of building blocks, folded into an exact three-dimensional shape. mAbs are the biggest class of biologic by sales, and many of the world’s top-selling medicines are injected biologics, not pills. Biologics you may know include insulin, autoimmune disease and cancer treatments, and notable drugs such as Humira, Keytruda, Herceptin.

This primer follows the largest and most established class – protein biologics, with monoclonal antibodies as the worked example – but the same three-stage manufacturing process (make it, purify it, fill it) underlies the newer modalities too.

As biotechnology advances, medicines continue to get more complex. Even with the most common form of biologic, a mAb, there is no practical way to assemble a 25,000-atom molecule one reaction at a time.

Biologics are some of the most important and expensive medicines, but they cannot be built by ordinary chemistry. And because a biologic is injected directly into the body (as opposed to pills that go through the digestive tract), its quality and safety are paramount – which is why the manufacturing process matters so much.

Why are biologics grown in living cells?

Since you cannot build the molecule, you get a living cell to make it for you.

Every cell already reads genes – the instructions for building proteins. And we learned how to direct a cell to produce a specific molecule. Then we give that cell the right conditions to multiply until there is enough of the molecule.

Simple proteins can be made by microbes – bacteria like E. coli, or yeast, the same organism used in brewing and baking (insulin is made this way). Bigger, more complex proteins like antibodies usually need a mammalian cell, most often the CHO cell (from Chinese hamster ovary). This is because a full antibody has to be both folded and assembled correctly and coated in human-like sugars (glycosylation); mammalian cells reliably do both, while microbes generally cannot.

The whole batch is grown from one starting cell – one parent cell that is cloned many times – so every copy has the same sequence. That is what monoclonal means: one clone, one antibody, copied over and over.

Getting to that one cell – engineering it, growing many copies, and picking the best producer – is a stage in itself, called cell line development. Because the cell line is effectively the recipe, it is one of the most closely guarded steps.

Once you have this cell line, the drug is simply whatever it makes.

How is a biologic manufactured?

Making a biologic has three main stages: grow, purify, fill.

• Upstream: cultivate and feed the parent cell to replicate itself into a big, dense batch that makes the molecule.
• Downstream: extract and filter the desired molecule (the drug substance, or the active ingredient) out of the cells.
• Fill-finish: stabilize & mix it into its final form, and fill it into vials or syringes as the drug product.

Upstream: how are the cells grown?

Upstream is growing in stages: one frozen vial of cells becomes a whole tankful.

You cannot fill a giant tank straight from a vial, so you build up to it. Start with one frozen vial, thaw into cell culture media (the cells’ food, a broth of sugars, amino acids, salts, and vitamins), and move through bigger and bigger vessels: a flask, then small tanks, then larger ones. This step-up is the seed train.

The last and biggest vessel is the production bioreactor – up to about 5,000 liters if it is a single-use plastic bag, or about 20,000 liters for the largest stainless steel tanks.

In the big tank, the cells multiply to their peak and make the molecule as they grow. The usual method is fed-batch: keep feeding the cells fresh nutrients and let the run go for two to three weeks, until waste builds up and growth stalls.

When the batch peaks, it is harvested and clarified: the cells and debris are spun out in a centrifuge, then the liquid is filtered and passed on. The molecule is now floating in that liquid.

If this sounds like brewing beer, that is no accident. A brewery grows yeast in a tank, keeps it warm, and feeds it sugar while the living cells do the work – and this industry has a similar process (the tanks are still sometimes called fermenters). The difference: in brewing, much of the byproduct is the product – the alcohol the yeast gives off, plus the rest of the liquid, is what you want (often what provides flavor and aroma). Here, the molecule you want is one thing floating among thousands, and everything else has to go. In medicine – especially injectables – the active ingredient has to be as pure as possible, with nothing left behind that could interfere with how the drug works or that could potentially harm the patient.

Downstream: how is the molecule purified?

The batch holds far more than your molecule, so downstream is a series of clean-up steps that strip out everything else.

That liquid holds your molecule plus thousands of others the cells made, their DNA, and leftover food. Downstream removes all of it, step by step. This is where brewing stops being a useful guide: beer gets filtered, but it is never purified down to a single molecule.

First, the molecule is separated from the cells – and in some instances, the cells are broken open (lysed) to release it. The liquid is then pushed through a column of packed beads – a technique called chromatography – where the beads carry Protein A resin, which grabs antibodies and lets everything else flow past. A buffer – one of the simple salt solutions used to wash and rinse at every step – then releases the antibody. This process with Protein A works so well that it is used for nearly every mAb production.

Next steps include: a viral-inactivation step (a short low-pH hold that disrupts and inactivates many viruses), further columns (polishing) that remove the last stray impurities, and fine filters that catch any remaining virus and concentrate the molecule. What comes out is the drug substance.

Fill-finish: how does it become a finished medicine?

The drug substance is the active ingredient; fill-finish turns it into the finished medicine.

The molecule is mixed with excipients – inactive ingredients that keep it intact – and filled, in sterile conditions, into vials, syringes, or pens. The molecule is fragile, so this mixing is not just packaging: it is what lets the drug survive months of storage and shipping and, finally, the injection. The result is the drug product – what a patient actually receives.

Note that the fill-finish elements are often outsourced to specialist fill-finish providers. The upstream and downstream processes to get to the drug substance are seen as the most proprietary. Fill-finish is about storing and stabilizing the drug before it is administered to the patient.

Why is the process approved, not just the drug?

Because the drug is grown by living cells and cannot be fully checked, the process itself becomes part of what is approved.

Here is the crux of it. You cannot fully verify a biologic by testing the finished molecule – it is too big and too varied to measure completely, and small changes in how it is made can change the drug in ways that matter for safety. As the FDA puts it, biologics are “complex mixtures that are not easily identified or characterized,” unlike a chemically synthesized drug, whose structure is known. Testing helps, but it is not enough. So the manufacturers keep the whole process fixed: the same cells, materials, and steps. The industry sums this up in one phrase – the process is the product.

The process is the product.

There is another good reason for all the scrutiny around the process: how the body receives the drug. A pill is swallowed, so the body has many layers of protection before it reaches the blood. A biologic is injected – into a vein, a muscle, or under the skin – going almost straight into the body and skipping those defenses. That makes biologics powerful – and unforgiving. Any impurity or contaminant travels almost straight into the bloodstream, so purity and sterility are critically important. This is why biologics are regulated strictly and why the process matters so much.

Because the whole workflow is part of the regulatory filing, a supplier or material written into the process during development tends to stay for the life of the drug. Swapping a critical component means re-validating with regulators, which is costly and risky. This is especially true for the parts that shape the product (the cells, the media, the Protein A resin) or that carry validated safety claims (the virus filters and sterilizing filters).

Takeaways

• A biologic is grown, not built. It is too large and complex to assemble by chemistry, so a living cell is directed to produce it.
• Making one has three stages: grow the cells (upstream), extract and purify the one molecule (downstream), and formulate and fill it (fill-finish).
• The process is the product. The manufacturing process itself is controlled and approved, and is a core part of the intellectual property.
• That locks the recipe in. The critical cells, materials, and suppliers designed in during development tend to stay for the life of the drug.